within Pharmacolibrary.Drugs.ATC.J;

model J01DB11
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.000125,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.018,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01DB11</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Cefroxadine is an oral first-generation cephalosporin antibiotic formerly used for the treatment of bacterial infections such as respiratory tract, urinary tract, and skin infections. Cefroxadine is not currently approved or widely used, with most clinical experience and data dating back to the 1970s and 1980s.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult individuals, based on known class effect of first-generation oral cephalosporins; no specific dedicated published PK study could be identified for cefroxadine.</p><h4>References</h4><ol><li><p>Kitagawa, S, &amp; Sugaya, Y (1996). Characteristics of uptake of cefroxadine by rabbit small intestinal brush border membrane vesicles. <i>Biological &amp; pharmaceutical bulletin</i> 19(2) 268–273. DOI:<a href=\"https://doi.org/10.1248/bpb.19.268\">10.1248/bpb.19.268</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8850320/\">https://pubmed.ncbi.nlm.nih.gov/8850320</a></p></li><li><p>Ohkawa, M, et al., &amp; Awazu, S (1981). Pharmacokinetics of cefroxadine in healthy volunteers and patients with impaired renal function. <i>Chemotherapy</i> 27(3) 149–154. DOI:<a href=\"https://doi.org/10.1159/000237971\">10.1159/000237971</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7226971/\">https://pubmed.ncbi.nlm.nih.gov/7226971</a></p></li><li><p>Nieto, MJ, et al., &amp; Macias, JF (1983). Elimination of cefroxadine (CGP-9000) from patients undergoing dialysis. <i>European journal of clinical pharmacology</i> 24(1) 109–112. DOI:<a href=\"https://doi.org/10.1007/BF00613936\">10.1007/BF00613936</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/6832192/\">https://pubmed.ncbi.nlm.nih.gov/6832192</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01DB11;
